FF-10502 is under clinical development by Fujifilm and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect FF-10502’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FF-10502 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

FF-10502 overview

FF-10502 is under development for the treatment of metastatic solid tumors, lymphoma, advanced/recurrent pancreatic and ovarian cancer, cholangiocarcinoma, parotid gland, prostate cancer, sarcoma, endometrial cancer, squamous cell carcinoma of the head and neck, anal, colon-neuroendocrine cancers. It is a synthetic pyrimidine nucleoside analogue administered through intravenous route. It acts by targeting DNA polymerase. It is based on the Fujifilm's organic synthesis technology.

Fujifilm overview

Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, document solutions and imaging systems. The company offers document solutions such as office products, office printers, and allied production services and global services. Its major products include color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, cell culture media and reagents, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. The company has business presence in the Americas, Europe, and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.

Quick View FF-10502 LOA Data

Report Segments
  • Innovator
Drug Name
  • FF-10502
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Fujifilm
  • Originator: Fujifilm
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.